Stockscreener 앱 받기
83.80
0.25%
0.10
전일 마감가:
$83.70
열려 있는:
$83.85
하루 거래량:
92,441
Relative Volume:
0.05
시가총액:
$16.38B
수익:
$4.58B
순이익/손실:
$870.87M
주가수익비율:
19.05
EPS:
4.4
순현금흐름:
$945.58M
1주 성능:
-1.33%
1개월 성능:
+8.44%
6개월 성능:
+14.16%
1년 성능:
+27.30%
1일 변동 폭
$83.41
$84.04
1주일 범위
$83.41
$85.87
52주 변동 폭
$53.56
$87.24
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
83.86 | 16.57B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.56 | 99.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.29 | 62.21B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.89 | 59.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
704.24 | 43.33B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
311.99 | 35.68B | 3.81B | -644.79M | -669.77M | -6.24 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Applying Elliott Wave Theory to Incyte CorporationJuly 2025 Market Mood & Low Risk High Reward Trade Ideas - Newser
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype? - sharewise.com
What indicators show strength in Incyte CorporationPortfolio Value Report & Free Accurate Trade Setup Notifications - Newser
Quantitative breakdown of Incyte Corporation recent moveEarnings Miss & Real-Time Volume Triggers - Newser
Long term hold vs stop loss in Incyte CorporationDividend Hike & Weekly High Return Stock Forecasts - Newser
Will Incyte Corporation stock recover after recent drop2025 Breakouts & Breakdowns & Free Reliable Trade Execution Plans - Newser
Should you wait for a breakout in Incyte CorporationQuarterly Growth Report & AI Driven Stock Reports - Newser
What candlestick patterns are forming on Incyte CorporationTrade Risk Report & Free Long-Term Investment Growth Plans - Newser
Detecting support and resistance levels for Incyte CorporationJuly 2025 Selloffs & Technical Confirmation Trade Alerts - Newser
How sentiment analysis helps forecast Incyte Corporation2025 Price Momentum & Short-Term Swing Trade Alerts - Newser
Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - MSN
Published on: 2025-08-28 10:23:57 - Newser
Evaluating Incyte Corporation with trendline analysis2025 Institutional Moves & Weekly Market Pulse Updates - Newser
Will breakout in Incyte Corporation lead to full recoveryDollar Strength & Capital Efficiency Focused Ideas - Newser
What’s the recovery path for long term holders of Incyte CorporationJuly 2025 Decliners & Breakout Confirmation Alerts - Newser
Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership - Insider Monkey
Can technical indicators confirm Incyte Corporation’s reversalJuly 2025 Trends & Target Return Focused Stock Picks - Newser
Reversal indicators forming on Incyte Corporation stock2025 Trading Volume Trends & Stock Timing and Entry Methods - Newser
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 27, 2025 - BioSpace
Chart based analysis of Incyte Corporation trends2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
Incyte reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Using RSI to spot recovery in Incyte CorporationMarket Trend Summary & Growth Focused Entry Reports - Newser
What institutional flow reveals about Incyte CorporationBull Run & Safe Capital Growth Plans - Newser
What Fibonacci levels say about Incyte Corporation reboundLayoff News & Safe Entry Zone Tips - Newser
Three Biotech Companies to Watch: Boston Scientific, Arcutis Biotherapeutics, and Incyte Corporation - AInvest
How institutional ownership impacts Incyte Corporation stockJuly 2025 Highlights & Safe Swing Trade Setup Alerts - Newser
Will Incyte Corporation rebound enough to break evenJuly 2025 Spike Watch & Weekly Setup with High ROI Potential - Newser
How to escape a deep drawdown in Incyte Corporation2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Incyte appoints Soni Basi as new chief human resources officer - Investing.com
Incyte Announces Executive Changes, Effective August 25, 2025 - MarketScreener
Incyte Corporation Company’s Quarterly Earnings Growth: What the Numbers SayQuarterly Profit Summary & Risk Controlled Daily Plans - Newser
Analyzing Incyte Corporation with risk reward ratio charts2025 Investor Takeaways & Real-Time Chart Breakout Alerts - Newser
How Incyte Corporation stock performs during market volatility2025 Major Catalysts & AI Optimized Trade Strategies - beatles.ru
Market Wrap: Is Incyte Corporation impacted by rising rates2025 Market Sentiment & Weekly High Momentum Picks - theviewers.co.kr
Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round - TheStreet
Incyte Corp. Stock Down Despite Market Surge - AInvest
JP Morgan Maintains Incyte (INCY) Rating, Raises Price Target to $73 | INCY Stock News - GuruFocus
Eli Lilly (LLY) Shares Lower After Update on Rheumatoid Arthritis Drug - TheStreet
JPMorgan Adjusts Price Target on Incyte to $73 From $67, Maintains Neutral Rating - MarketScreener
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.01%
자본화:
|
볼륨(24시간):